Norstella

Norstella introduces NorstellaLinQ: https://ow.ly/nqga50TGawG. It's biopharma’s first fully integrated data asset combining RWD—open and closed claims, lab results and EMR—with Norstella’s proprietary forecasting, clinical, regulatory, payer, coverage and commercial intelligence data. Get closer to the patient than ever before. Learn more about NorstellaLinQ at the link in this post.

The healthcare landscape is always evolving, but MMIT’s mission stays the same: We’re dedicated to helping clients solve their market access challenges. Learn more: https://ow.ly/qeEm50VhBP0

Infographic Download: Learn about the biggest hurdles and innovations in rare disease drug development by downloading our infographic: https://ow.ly/eOaU50V8xnZ More than 395 million people worldwide are affected by rare diseases, yet only 5% have an FDA-approved treatment. The road from pipeline to patient is filled with challenges — from small patient populations to complex regulatory pathways — but change is happening. This infographic explores the biggest hurdles in rare disease drug development and the innovations reshaping the landscape. It examines how AI, data-sharing, and patient-driven research are transforming drug discovery, how new clinical trial models are improving patient recruitment and retention, and how regulatory collaboration is accelerating approvals. Discover how technology, strategy, and patient advocacy are driving progress. Download the infographic now at the link in this post. #Norstella #Pipeline2Patient

Hot Job Alert: Senior HR Business Partner at Norstella! Get the details: https://ow.ly/5HQk50VjwFB Job description: We're looking for a talented and passionate Senior HR Business Partner to join the Norstella team and support our dynamic commercial global organization. This person will be a strategic partner to the business, working with them to develop and implement plans that align with organizational goals to increase effectiveness and efficiency for the commercial organization. They will work closely with commercial leadership to advise on all aspects of HR, including talent management, employee development, and other talent initiatives.  If this sounds like the perfect role for you, apply now or share this opportunity with someone who might be interested!

Pharma’s biggest trends are here: https://ow.ly/ysOg50VjYbO. The 33rd annual Pharma R&D Review covers it all—pipeline shifts by company, therapeutic area, and drug type. Whether you're monitoring competitors or planning your next move, this report has the insights you need.
 Get the full report now: https://ow.ly/ysOg50VjYbO #RD25 _____ Follow Citeline, the leading provider of drug, device, company, clinical trial, and market intelligence in the pharmaceutical and medtech markets.

Daniel Chancellor, VP of Thought Leadership, recently penned an article for The Medicine Maker on data proliferation and the imperative to connect the dots for smarter decision-making. https://ow.ly/y1mG50Vjvb1 This is where NorstellaLinQ comes in as the biopharma industry's first fully integrated data asset. Click the link in this post to read the full article.

Norstella has been named to Fast Company's list of the World’s Most Innovative Companies for 2025, highlighting our unwavering commitment to securing patient access to life-saving treatments and revolutionizing the pharma intelligence landscape. https://ow.ly/Juk250Vj7L7 Read our press release to find out more about this recognition. #FCMostInnovative

Reflections on AAD 2025: Key Takeaways from Orlando AAD 2025 just wrapped up under the beautiful Orlando sunshine, bringing together nearly 18,000 attendees for one of the most important dermatology conferences of the year. Here are some key highlights that stood out: ✅ GLP-1 Agonists & Systemic Treatments in Psoriasis There’s growing interest in the role of weight control via GLP-1 agonists in improving responses to systemic treatments for severe psoriasis. Ongoing clinical trials will provide more insights into this potential synergy. ✅ Icotrokinra: A Game Changer? As an oral IL-23R antagonist, Icotrokinra could shake up the psoriasis treatment landscape, which is currently dominated by injectables. ✅ Atopic Dermatitis: A Highly Heterogeneous Disease Different patient profiles call for tailored treatments. While anti-IL-31R Nemluvio targets itch, other options, such as anti-IL-4/13, anti-IL-13, and JAK inhibitors, focus on treating erythematous skin in different patient populations. ✅ Novel targets for Atopic Dermatitis: Anti-OX40 therapies Emerging anti-OX40 therapies (rocatinlimab and amlitelimab) are in fierce competition. Phase 3 topline data for anti-OX40 agents are expected in 2026, with potential for sustained efficacy months after treatment withdrawal. ✅ JAK Inhibitors: Balancing Risk & Benefit Despite ongoing debates around cardiovascular and malignancy risks, some dermatologists advocate for JAK inhibitors (oral & topical) in psoriasis, atopic dermatitis, hidradenitis suppurativa, prurigo nodularis, and alopecia areata. Some clinicians are even combining oral JAK inhibitors with biologics for a rapid skin clearance, followed by a tapering strategy, as mentioned in an offline discussion. ✅ Alopecia Areata: The Importance of Early Treatment Experts emphasized that early intervention leads to better treatment outcomes for alopecia areata, reinforcing the need for timely diagnosis and management. ✅ Biologic Boom & Women’s Health With biologics transforming dermatology, there’s a pressing need for more research on their safety in pregnant and breastfeeding patients, given that a significant portion of dermatology patients are women of childbearing age. As dermatology continues to evolve, these insights from AAD 2025 highlight the need for personalized, data-driven, and patient-centered approaches. Exciting times ahead for dermatology innovation! #AAD2025 #Dermatology #Psoriasis #AtopicDermatitis #Biologics #JAKinhibitors

Hot Job Alert: VP, Strategic Accounts for MMIT (Managed Markets Insight & Technology) (Remote) - Apply here: https://ow.ly/cwHh50ViojT Job Overview: As a Vice President, Strategic Accounts, you will play a pivotal role in building new relationships, selling our solutions, and serving as a trusted partner to high-value clients in the life sciences industry. You’ll act as a trusted advisor to senior-level stakeholders, understanding their complex needs and helping them to leverage our solutions to enhance their business goals. Excited about this role? Apply now or share with someone who would be!

China has started appearing as the key player in the clinical trial landscape globally in terms of the growing number of global clinical trials initiated in the country. https://ow.ly/PJCZ50UkfBt Janelle Hart, Managing Editor, Custom Content at Citeline, a Norstella company, sits down with Xu Hu and Jie (Dexter) Yan, senior APAC reporters at Citeline, to discuss key trends and ongoing barriers impacting drug development in China and the future Chinese pharma market. Click the link in this post for access to the full article. #ClinicalTrials #ChinaBiotech #APACPharma #BiotechTrends #PharmaceuticalResearch